Compare Bristol-Myers Squibb Co (BMY) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.57 (market cap $116.30B), while iShares 20 Plus Year Treasury Bond ETF trades at $84.23. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | TLT | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $92.06 |
52-Week Low | $42.60 | $83.02 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT trades at $83.97, down 0.59% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as fixed income sees renewed interest amid economic uncertainty. Recent dividend payments of $0.32-$0.34 highlight income generation, while technical indicators show oversold conditions with RSI at 27.67 suggesting potential rebound opportunity.
Long-term Treasury bonds offer attractive yields but face interest rate sensitivity. The Fed's hawkish stance presents near-term headwinds, though TLT's 4-5x higher starting yields than pre-crisis levels provide income appeal. Investors must weigh duration risk against potential Fed policy shifts and inflation trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
